Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.
2.

Polyubiquitination of p53 by a ubiquitin ligase activity of p300.

Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, Tagami H, Nakatani Y, Livingston DM.

Science. 2003 Apr 11;300(5617):342-4.

3.

Inhibition of p53 degradation by Mdm2 acetylation.

Wang X, Taplick J, Geva N, Oren M.

FEBS Lett. 2004 Mar 12;561(1-3):195-201.

4.

Stabilization and activation of p53 by the coactivator protein TAFII31.

Buschmann T, Lin Y, Aithmitti N, Fuchs SY, Lu H, Resnick-Silverman L, Manfredi JJ, Ronai Z, Wu X.

J Biol Chem. 2001 Apr 27;276(17):13852-7. Epub 2001 Feb 1.

5.

p300/MDM2 complexes participate in MDM2-mediated p53 degradation.

Grossman SR, Perez M, Kung AL, Joseph M, Mansur C, Xiao ZX, Kumar S, Howley PM, Livingston DM.

Mol Cell. 1998 Oct;2(4):405-15.

6.

MDM2 mediates p300/CREB-binding protein-associated factor ubiquitination and degradation.

Jin Y, Zeng SX, Lee H, Lu H.

J Biol Chem. 2004 May 7;279(19):20035-43. Epub 2004 Feb 9.

7.

MDM2 suppresses p73 function without promoting p73 degradation.

Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X, Kaelin WG Jr, Oren M, Chen J, Lu H.

Mol Cell Biol. 1999 May;19(5):3257-66.

8.

Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.

Rodriguez MS, Desterro JM, Lain S, Lane DP, Hay RT.

Mol Cell Biol. 2000 Nov;20(22):8458-67.

9.
10.

Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination.

Nie L, Sasaki M, Maki CG.

J Biol Chem. 2007 May 11;282(19):14616-25. Epub 2007 Mar 19.

11.

HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation.

Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC.

Nat Cell Biol. 2001 Nov;3(11):973-82. Erratum in: Nat Cell Biol 2002 Sep;4(9):736.

PMID:
11715018
12.
13.

MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding.

Inoue T, Geyer RK, Howard D, Yu ZK, Maki CG.

J Biol Chem. 2001 Nov 30;276(48):45255-60. Epub 2001 Sep 25.

14.
15.

Characterization of an E1A-CBP interaction defines a novel transcriptional adapter motif (TRAM) in CBP/p300.

O'Connor MJ, Zimmermann H, Nielsen S, Bernard HU, Kouzarides T.

J Virol. 1999 May;73(5):3574-81.

16.

Promoter specificity and stability control of the p53-related protein p73.

Lee CW, La Thangue NB.

Oncogene. 1999 Jul 22;18(29):4171-81.

17.

MDM2-dependent ubiquitination of nuclear and cytoplasmic P53.

Yu ZK, Geyer RK, Maki CG.

Oncogene. 2000 Nov 30;19(51):5892-7.

PMID:
11127820
18.
19.

Defective p53 post-translational modification required for wild type p53 inactivation in malignant epithelial cells with mdm2 gene amplification.

Knights CD, Liu Y, Appella E, Kulesz-Martin M.

J Biol Chem. 2003 Dec 26;278(52):52890-900. Epub 2003 Oct 10.

20.

YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress.

Grönroos E, Terentiev AA, Punga T, Ericsson J.

Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12165-70. Epub 2004 Aug 4.

Supplemental Content

Support Center